DXCM
Dexcom Inc Health Care Surgical & Medical Instruments & Apparatus S&P 500Nasdaq-100Russell 3000
$82.29Close
$31.7BMarket cap
$54.84 – $92.3452-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, RS under 70
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
11%
1wk
up 5.6%
price change
1mo
down 4.6%
price change
12-month return
up 21%
market up 11% ·
its own up 10%
F-score
8 / 9
Exceptional
Altman Z
7.39
Low risk
P/E
37.9×
price / earnings
PEG
0.79
P/E / EPS growth
P/B
11.5×
price / book
Earnings yield
up 3.0%
EBIT / enterprise value
Cheaper than
36%
of the market · expensive
Revenue growth
up 16%
year on year
EPS growth
up 3%
latest quarter · -42 pts
Sales growth
up 11%
latest quarter · -2 pts
ROE
up 34%
return on equity
Free cash margin
up 23%
$1.1B FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-0.8×
net cash
Interest cover
63.8×EBIT / interest
Piotroski tests
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- no new shares issued
- assets working harder
Trade setup
ATR%
3.2%
$2.61 a day · 2×ATR $77.08
RS
65 / 99
vs the universe
Trend
6 / 8
under the 50-day, RS under 70
Relative volume
2.1×
vs 50-day average
Up/down volume
0.93
50 sessions
Implied move
—
no scheduled report
Trend template · 6 of 8
- Price above the 50-day average: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+7% vs market2 sessions after results
Options
$717,46539.9% IV · activity
Financials
- Gross 60%
- Net 18%
- Free cash 23%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9B | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| Gross margin | 66% | 69% | 65% | 63% | 60% | 60% |
| Operating income | $299.5M | $265.8M | $391.2M | $597.7M | $600.0M | $911.8M |
| Net income | $549.7M | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| Net margin | 29% | 9% | 12% | 15% | 14% | 18% |
| Earnings per share | $1.31 | $0.51 | $0.80 | $1.27 | $1.40 | $2.06 |
| Free cash flow | $276.6M | $53.3M | $304.7M | $511.9M | $630.7M | $1.1B |
| Free cash margin | 14% | 2% | 10% | 14% | 16% | 23% |
| Cash | $817.6M | $1.1B | $642.3M | $566.3M | $606.1M | $917.7M |
| Shareholders' equity | $1.6B | $2.0B | $2.1B | $2.1B | $2.1B | $2.7B |
| Shares outstanding | 384.40m | 388m | 386.30m | 385.40m | 390.70m | 384.80m |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $76 – $91 ±9.5% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- About the same 39.9% priced · 39.9% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- About the same
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $717,465 calls $559,514 · puts $157,950 · latest session
- 0.28× -1.03 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls -2k · puts +1.98k past week
For options traders: ATM IV 39.9% (-8.8% 1w) · 1m ÷ 3m IV 1.01 · 25Δ skew 4.6 pts · Net GEX $1.4M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 12, 2026 | Annual ↗ | Dec 31, 2025 | 43d |
| Oct 30, 2025 | Quarterly ↗ | Sep 30, 2025 | 30d |
| Jul 30, 2025 | Quarterly ↗ | Jun 30, 2025 | 30d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 18, 2025 | Annual ↗ | Dec 31, 2024 | 49d |
| Oct 24, 2024 | Quarterly ↗ | Sep 30, 2024 | 24d |
| Jul 25, 2024 | Quarterly ↗ | Jun 30, 2024 | 25d |
| Apr 25, 2024 | Quarterly ↗ | Mar 31, 2024 | 25d |
| Feb 8, 2024 | Annual ↗ | Dec 31, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results · Other events ↗ |
| Sep 14, 2026 | Director or officer change · Regulation FD ↗ |
| Sep 10, 2026 | Director or officer change · Regulation FD ↗ |
| Jul 30, 2026 | Results ↗ |
| May 28, 2026 | Shareholder vote ↗ |
| May 15, 2026 | Regulation FD · Other events ↗ |
| Apr 30, 2026 | Results ↗ |
| Mar 2, 2026 | Director or officer change ↗ |
| Feb 26, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 12, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Dec 22, 2025 | Director or officer change ↗ |